| 6th Aug 2025 6:00 am |
MFN |
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43% |
| 2nd Jul 2025 10:00 am |
MFN |
Faron Pharmaceuticals Ltd: Director Dealing |
| 30th Jun 2025 11:00 am |
MFN |
Faron Pharmaceuticals Ltd: Director/PCA Dealing |
| 5th Jun 2025 3:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation |
| 3rd Jun 2025 11:00 am |
MFN |
Faron Pharmaceuticals Ltd: Registration of New Shares |
| 3rd Jun 2025 6:00 am |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds |
| 27th May 2025 4:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company |
| 21st May 2025 6:00 am |
MFN |
Faron Appoints Ralph Hughes as Chief Business Officer (CBO) |
| 14th May 2025 1:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Grant of Options |
| 17th Apr 2025 12:15 pm |
MFN |
Holding in Company |
| 15th Apr 2025 6:00 am |
MFN |
Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome |
| 3rd Apr 2025 6:00 am |
MFN |
Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million |
| 21st Mar 2025 1:15 pm |
MFN |
Board Changes |
| 21st Mar 2025 11:45 am |
MFN |
Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM |
| 20th Mar 2025 7:00 am |
MFN |
Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be elected |
| 3rd Mar 2025 12:05 pm |
RNS |
FDA Grants Orphan Drug Designation |
| 3rd Mar 2025 12:00 pm |
MFN |
Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS |
| 28th Feb 2025 12:00 pm |
MFN |
NOTICE OF FARON PHARMACEUTICALS LTD'S ANNUAL GENERAL MEETING |
| 28th Feb 2025 12:00 pm |
RNS |
Notice of Annual General Meeting |
| 27th Feb 2025 7:30 am |
MFN |
Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syndrome (MDS) |
| 27th Feb 2025 7:30 am |
RNS |
Positive EMA Opinion on Orphan Drug Designation |
| 27th Feb 2025 7:15 am |
RNS |
Annual Report 2024 published |
| 27th Feb 2025 7:15 am |
MFN |
Faron Pharmaceuticals Ltd's Annual Report 2024 published |
| 27th Feb 2025 7:00 am |
RNS |
Financial Statement 1 January to 31 December 2024 |
| 27th Feb 2025 7:00 am |
MFN |
Faron's Financial Statement Release 1 January to 31 December 2024 |
| 19th Feb 2025 10:00 am |
RNS |
Notice of Financial Statement and Annual Report |
| 14th Feb 2025 12:00 pm |
MFN |
Holding(s) in Company |
| 14th Feb 2025 12:00 pm |
RNS |
Holding(s) in Company |
| 11th Feb 2025 7:30 am |
MFN |
Change of Broker |
| 11th Feb 2025 7:30 am |
RNS |
Change of Broker |
| 6th Feb 2025 3:00 pm |
MFN |
Holding(s) in Company |
| 6th Feb 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 6th Feb 2025 7:00 am |
RNS |
Results of Oversubscribed Placing |
| 6th Feb 2025 7:00 am |
MFN |
Results of the Significantly Oversubscribed Placing |
| 5th Feb 2025 4:30 pm |
MFN |
Proposed Issue and Placing |
| 5th Feb 2025 4:30 pm |
RNS |
Proposed Issue and Placing |
| 31st Jan 2025 7:00 am |
RNS-R |
Final Patient Identified for BEXMAB Phase II Study |
| 13th Dec 2024 7:00 am |
RNS |
Faron’s Financial Calendar for 2025 |
| 27th Nov 2024 7:00 am |
RNS |
Positive Phase 2 Interim Results from BEXMAB Trial |
| 5th Nov 2024 7:00 am |
RNS |
Shareholders’ Nomination Board |
